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OBJECTIVE — Restoration of insulin secretion is critical for the treatment of type 2 diabetes.
Exerciseanddietcanalterglucose-inducedinsulinresponses,butwhetherthisisduetochanges
in -cell function per se is not clear. The mechanisms by which lifestyle intervention may modify
insulin secretion in type 2 diabetes have also not been examined but may involve the incretin axis.
RESEARCH DESIGN AND METHODS — Twenty-nine older, obese (aged 65  1
years; BMI 33.6  1.0 kg/m
2) subjects, including individuals with newly diagnosed type 2
diabetes (obese-type 2 diabetic) and individuals with normal glucose tolerance (obese-NGT),
underwent 3 months of nutritional counseling and exercise training. -Cell function (oral glucose–
induced insulin secretion corrected for insulin resistance assessed by hyperinsulinemic-euglycemic
clamps) and the role of glucose-dependent insulinotropic polypeptide (GIP) were examined.
RESULTS — After exercise and diet-induced weight loss (5.0  0.7 kg), oral glucose–
induced insulin secretion was increased in the obese-type 2 diabetic group and decreased in the
obese-NGT group (both P  0.05). When corrected for alterations in insulin resistance, the
change in insulin secretion remained signiﬁcant only in the obese-type 2 diabetic group (1.23 
0.26vs.2.040.46arbitraryunits;P0.01).Changesininsulinsecretionweredirectlyrelated
to the GIP responses to oral glucose (r  0.64, P  0.005), which were augmented in the
obese-type 2 diabetic group and only moderately suppressed in the obese-NGT group.
CONCLUSIONS — After lifestyle-induced weight loss, improvements in oral glucose–
induced insulin secretion in older, obese, nondiabetic subjects seem to be largely dependent on
improved insulin sensitivity. However, in older obese diabetic patients, improved insulin secre-
tion is a consequence of elevated -cell function. We demonstrate for the ﬁrst time that changes
in insulin secretion after lifestyle intervention may be mediated via alterations in GIP secretion
from intestinal K-cells.
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iet and exercise-based lifestyle in-
terventions, such as the Diabetes
Prevention Program, have been
shown to successfully reduce the risk of
developing diabetes (1). Insulin resis-
tance is the major underlying defect driv-
ing hyperglycemia, the reversal of which
is critical to reduce vascular complica-
tions and mortality (2). However, in ad-
dition to insulin resistance, progressive
pancreatic -cell dysfunction, marked by
a decline in compensatory hyperinsulin-
emia across the glucose tolerance contin-
uum, ultimately results in type 2 diabetes
(3).
Previous work has highlighted the
beneﬁcial effects of lifestyle interventions
oninsulinsecretionand-cellfunctionin
obesity (4–7). However, it is rather well
establishedthatlargeimprovementsinin-
sulin resistance occur after exercise
and/or caloric restriction in obese non-
diabetic and diabetic humans (8–10).
Therefore, apparent changes in glucose
tolerance and insulin secretion may be
due to alterations in insulin resistance
that expose the pancreas to less glucose,
rather than intrinsic improvements in
-cell function.
Evidence suggests that postprandial
insulin secretion may be partially con-
trolled by nutrient-responsive incretin
peptides released by intestinal cells. We
recently reported that weight loss–
inducedreductionsininsulinsecretionin
obese men and women with impaired
glucose tolerance, are related to changes
in secretion of the incretin hormone glu-
cose-dependent insulinotropic polypep-
tide (GIP) (11). Indeed, bariatric surgery
restores insulin secretory capacity in pa-
tients with type 2 diabetes via alterations
in incretin secretion, including GIP (12).
Further, exenatide-based incretin-
mimetic pharmaceutical therapy also re-
storesinsulinsecretion(13).Theserecent
ﬁndings have indicated that the intrave-
nous methods used previously to study
insulinsecretion,methodsthatbypassthe
incretin-releasing gastrointestinal system,
may not be appropriate to study in vivo
mechanisms of lifestyle-induced change
in -cell function.
Inobese,insulin-resistantindividuals
exhibiting basal and postprandial hyper-
insulinemia, an improvement in -cell
function is regarded as a reduction of in-
sulin hypersecretion. Conversely, in type
2diabetesthecompensatorypostprandial
hyperinsulinemia required to correct for
the severe underlying insulin resistance is
absent, and therefore an increase in insu-
lin secretion would reﬂect an improve-
ment in -cell function. However, to
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tion per se, one must account for changes
in the -cell exposure to glucose by as-
sessing changes in insulin sensitivity. To
date, the potential of nonsurgical and
nonpharmacological lifestyle interven-
tions to preserve -cell function and in-
crease insulin secretion in type 2 diabetes
have not been fully explored. In addition,
there is a paucity of data on the effects of
exercise on incretin-mediated insulin se-
cretion. In this investigation, we exam-
ined the effects of diet and exercise-
induced weight loss on insulin resistance
andinsulinsecretioninolderobesetype2
diabetic individuals, compared with an
age- and BMI-matched obese control
group exhibiting normal glucose toler-
ance (NGT) and compensatory hyperin-
sulinemia.Wehypothesizedthatintype2
diabetes,inadditiontorelieffromtheun-
derlying insulin resistance, -cell insulin
secretory function would be elevated in
line with elevations in GIP secretion.
RESEARCH DESIGN AND
METHODS— Older obese men and
women (n  29; aged 65  1 years; BMI
33.6  1.0 kg/m
2) (Table 1) were re-
cruited from the local community to par-
ticipate in our ongoing obesity and
diabetes studies. All participants were
screenedwithamedicalhistoryandphys-
ical examination, blood and urine chem-
istry analyses, an oral glucose tolerance
test (OGTT), and a resting and exercise
stress test 12-lead electrocardiogram. In-
dividuals were excluded from participa-
tion if they 1) smoked, 2) were weight
unstable(2kginprevious6months),3)
undertook regular exercise (30 min/
day,3days/week),4)hadcontraindica-
tions to elevated levels of physical activity
as indicated by an electrocardiogram, 5)
demonstrated any evidence of current or
previous hematological, renal, hepatic,
cardiovascular, or pulmonary disease, or
6) were taking medications known to af-
fect our primary outcome variables. All
participants also underwent resting met-
abolic rate testing by indirect calorimetry
to calculate caloric requirements for the
intervention. Participants were stratiﬁed
into two age- and BMI-matched groups
according to their oral glucose tolerance:
those with NGT exhibiting insulin resis-
tance with compensatory hyperinsulin-
emia (obese-NGT) and those with newly
diagnosed type 2 diabetes (obese-type 2
diabetic) (2). Diabetic participants were
only identiﬁed by our screening proce-
dures, and their diabetes had not been
previously diagnosed nor were they tak-
ing blood glucose-lowering medications.
Signed informed consent was obtained
before enrollment into the study, and all
procedureswereapprovedbyourinstitu-
tional review board.
Lifestyle intervention. All participants
were entered into a 3-month diet and ex-
ercise-induced weight loss intervention.
These approaches are routine in our lab-
oratory and have been described in detail
previously (8).
Diet counseling. Prestudy nutritional
habits were assessed using 3-day diet
records, and subjects underwent weekly
counseling with a registered dietitian. Di-
etary habits were continuously assessed
throughout the intervention. The intent
of the counseling was to moderately re-
duce total caloric intake (300 kcal/day)
and to optimize the macronutrient com-
position. Nutritional analysis was per-
formed using Nutritionist Pro (Axxya
Systems, Stafford, TX).
Exercise training. Subjects also partook
in fully supervised aerobic treadmill-
walking exercise that was conducted for
1 h/day, 5 days/week. Initial sessions
were completed at 60–65% of maxi-
mum heart rate; however, by week 4,
intensity was increased and maintained
at 80–85% maximum heart rate. Exer-
cise intensity was calculated from data
collected during maximal aerobic exercise
tests conducted at biweekly intervals
throughout the intervention (described
below).
Prestudy/poststudy control period.
Metabolictestingwasconductedduringa
3-day inpatient stay in the Clinical Re-
searchUnit.Duringthisperiod,isocaloric
(based on resting metabolic rate multi-
plied by 1.2) meals (55% carbohydrate,
30% fat, and 15% protein) were pro-
vided. Compliance with these meals was
estimated by food weigh backs. Nonhab-
itual physical activity was also restricted
during the prestudy inpatient period.
Table 1—Subject characteristics of each of the age- and BMI-matched groups
Subject characteristics
Obese-NGT Obese-type 2 diabetic ANOVA
Prestudy Poststudy Prestudy Poststudy Time Time-group
Age (years) 63  26 7  2— —
Sex (male/female) 8/8 6/7 — —
Weight (kg) 93.9  3.2 88.8  2.9 98.3  4.6 93.4  4.2 0.0001 0.90
BMI (kg/m
2) 32.1  1.1 30.4  1.2 35.5  1.5 33.7  1.3 0.0001 0.78
Fat (%) 41.0  1.6 39.0  2.1 40.8  2.0 38.5  2.5 0.01 0.84
VAT (cm
2) 187  16 134  15 202  28 168  27 0.0001 0.24
Vo2max (l/min) 2.11  0.12 2.35  0.16 1.99  0.15 2.25  0.15 0.0001 0.97
Leptin (ng/ml) 25.9  4.8 19.9  4.4 22.3  4.7 18.5  4.3 0.007 0.40
TG (mg/dl) 194  28 136  19 181  17 156  19 0.003 0.15
Cholesterol (mg/dl) 199  9 178  8 192  10 182  9 0.0006 0.24
A1C (%) 5.35  0.09 5.51  0.08 5.86  0.29 5.16  0.32 0.08 0.008
FPG (mg/dl) 97.9  3.5 97.2  3.0 129  7* 116  6 0.03 0.04
2-h OGTT (mg/dl) 124  3 122  7 225  11* 192  11 0.03 0.05
FPI (U/ml) 16.0  2.0 13.7  2.3 26.5  7.1 17.4  1.5 0.11 0.27
A U CI(  10
3 U/ml   0.3 h) 12.9  1.6 7.6  1.6 10.1  2.3 11.5  1.9 0.01 0.13
GDR (mg/kg/min) 2.67  0.26 3.91  0.38 1.85  0.37* 2.34  0.40 0.0001 0.03
Data are means  SEM. *Indicates signiﬁcant difference vs. obese-NGT, P  0.05. AUC I, area under the insulin response curve to the OGTT; FPI, fasting plasma
insulin; GDR, glucose disposal rate during the hyperinsulinemic-euglycemic clamp; TG, triglycerides; VAT, intra-abdominal visceral adipose tissue.
Weight loss, -cell function, and GIP
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sures. To determine body composition,
weightandheightweremeasuredbystan-
dard techniques. Whole-body fat per-
centage was determined using dual-
energy X-ray absorptiometry (iDXA;
Lunar, Madison, WI). Computed tomog-
raphy scanning (Picker PQ6000 scanner;
Marconi/Picker, Highland Heights, OH)
was used to measure cross-sectional vis-
ceral abdominal adiposity at the fourth
lumbar vertebral body, as described pre-
viously (8).
Aerobic ﬁtness. VO2max (Jaeger Oxycon
Pro; Viasys, Yorba Linda, CA) measured
during exhaustive exercise was used as a
marker of aerobic ﬁtness. These measure-
mentswererepeatedatbiweeklyintervals
to adjust training intensity in relation to
changes in aerobic ﬁtness. These proce-
dureshavebeenfullydescribedelsewhere
(8).
Oral glucose–induced insulin
secretion
A 3-h 75-g OGTT was administered at
8:00 A.M., after an overnight fast. Blood
samples were obtained from an intrave-
nous antecubital line at 30-min intervals.
Incremental metabolite responses (area
under the curve) during the OGTT were
calculatedusingthetrapezoidalrule.Oral
glucose–induced insulin secretion (re-
ferred to throughout as 	C-Pep/	G) was
calculated as incremental plasma C-
peptide (picomoles per liter) during the
ﬁrst 30 min of the OGTT divided by in-
cremental plasma glucose (millimoles per
liter)duringtheﬁrst30minoftheOGTT.
This is a slight modiﬁcation of a previous
model presented by Abdul-Ghani et al.
(14), based on the principle that changes
inC-peptidemoreaccuratelyreﬂectinsu-
lin secretion rates. In addition, early-
phase GIP secretion was estimated as the
incremental peptide response during the
ﬁrst 30 min of the OGTT (	GIP0–30).
Insulin sensitivity
A 2-h hyperinsulinemic euglycemic (90
mg/dl) clamp was performed after an
overnight fast, as described previously
(15). In brief, a primed continuous 40 mU  
m
2   min
1 infusion of insulin (Humu-
lin R U-100; Eli Lilly, Indianapolis, IN)
wasadministeredviaanantecubitalintra-
venous line, while a variable rate glucose
(20% w/v) infusion was simultaneously
administered to titrate ﬂuctuations in
plasma glucose. Arterialized plasma sam-
ples were obtained every 5 min from a
retrograde intravenous dorsal line in a
hand warmed to 
60°C. Alterations to
the glucose infusion rate were calculated
as described previously (15). Peripheral
tissue insulin sensitivity was estimated as
the mean space-corrected glucose disposal
rate over the last 30 min of the clamp.
-Cell function
Becauseofthehyperbolicrelationshipbe-
tween insulin secretion and sensitivity
across the glucose tolerance continuum
(3),themagnitudeoftheinsulinresponse
tooralglucoseisinﬂuencedbytheunder-
lying state of insulin resistance. Thus, to
estimate-cellfunction,wecorrectedour
measurements of insulin secretion (	C-
Pep/	G) for the prevailing insulin resis-
tance (IR) to derive an insulin secretion-
to-insulin resistance index (	C-Pep/
	G  IR) equivalent to the disposition
index of Gastaldelli et al. (16). Insulin re-
sistance was calculated as the inverse of
glucose disposal rate (micromoles per ki-
logram fat-free mass per minute) divided
by the late-phase plasma insulin (pico-
moles per liter) response during the hy-
perinsulinemic-euglycemic clamp. In our
subjects,weconﬁrmedthatbaselineinsu-
lin resistance was indeed related to insu-
lin secretion (r  0.78, P  0.001). In
addition, hepatic insulin extraction was
estimated as the incremental (area under
the curve) plasma C-peptide response
during the ﬁrst 30 min of the OGTT di-
vided by the incremental plasma insulin
response during the ﬁrst 30 min of the
OGTT (17).
Analytical chemistry
Plasmaglucosewasmeasuredusingaglu-
cose oxidase assay (YSI 2300 STAT Plus;
YSI, Yellow Springs, OH). Plasma insulin
and leptin concentrations were deter-
mined by radioimmunoassay (Millipore,
Billerica, MA). Plasma triglycerides and
total cholesterol were analyzed on an au-
tomated platform (Roche Modular Diag-
nostics, Indianapolis, IN). Total plasma
GIP (n  10 patients with NGT; n  8
patients with type 2 diabetes) and C-
peptide were assayed using an ELISA
(Linco Research, St. Charles, MO). A1C
was measured using nonporous ion-
exchange high-pressure liquid chroma-
tography (G7 HPLC analyzer; Tosoh
Bioscience, San Francisco, CA).
Statistics
Statistical analyses were performed using
Statview(SASInstitute,Cary,NC),andall
data are expressed as means  SEM. To
examine differences in prestudy variables
between groups, one-way ANOVA was
used to compare means. Between-group
(obese-NGT vs. obese-type 2 diabetic)
changesforallvariableswereanalyzedus-
ing two-way repeated-measures ANOVA.
Bonferroni post hoc tests were applied to
signiﬁcant group  time interactions to
identify speciﬁc statistical differences be-
tween means. The addition of sex as a co-
variate did not reveal any group  sex 
time interactions. Potential relationships
between variables were analyzed using
linearregressionmodels.Statisticalsignif-
icance was accepted when P  0.05.
RESULTS— Twenty-nine older obese
adults were successfully screened into
thisstudy:n16obese-NGT(8menand
8 women) and n  13 obese-type 2 dia-
betic (6 men and 7 women) individuals
(Table 1). Attendance at exercise training
sessions was 96.9  0.6%.
Body composition and aerobic
ﬁtness
Both obese-NGT and obese-type 2 dia-
betic groups demonstrated signiﬁcant
weight loss and reductions in whole body
and visceral fat (P  0.05) (Table 1).
VO2max also improved (P  0.05) (Table
1), demonstrating excellent compliance
and response to the exercise training pro-
gram. No group differences were observed
in body composition or aerobic ﬁtness.
Blood chemistry
All subjects exhibited signiﬁcant reduc-
tions in plasma leptin, triglycerides, and
cholesterol after the intervention (P 
0.05) (Table 1). A1C showed a nonsignif-
icant fall in the obese-type 2 diabetic
group.
Dietary intake
Compared with subjects’ prestudy diet
records, during the intervention total ca-
loric intake was signiﬁcantly reduced
(342.9  90.3 kcal/day; P  0.05) as
was fat intake (4.7  1.2% kcal; P 
0.05). No differences were noted in di-
etary habits between groups.
Insulin action and -cell function
Participants’fastingplasmaglucose(FPG)
and 2-h plasma glucose during the OGTT
(2-h OGTT) are shown in Table 1. At
baseline, the obese-type 2 diabetic group
exhibited fasting and postprandial hyper-
glycemia compared with the obese-NGT
group (P  0.05). After the intervention,
there were signiﬁcant decreases in FPG
and 2-h OGTT in the obese-type 2 dia-
Solomon and Associates
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ments were reﬂected in the changes in
plasma glucose responses to the OGTT
(area under the glucose curve) (Fig. 1A).
Baseline plasma C-peptide responses to
OGTT were markedly lower in the obese-
type 2 diabetic group than in the obese-
NGT group (P  0.05) (Fig. 1B).
Postintervention, C-peptide responses
were signiﬁcantly increased in the obese-
type2diabeticgroupanddecreasedinthe
obese-NGT group (both P  0.05) (Fig.
1B). At baseline, hepatic insulin extrac-
tion was decreased in the obese-type 2
diabetic group versus the obese-NGT
group (8.96  1.34 vs. 2.77  0.62; P 
0.05). Insulin extraction was unaffected
by the intervention. Changes in oral glu-
cose–induced insulin secretion (	C-Pep/
	G) are depicted in Fig. 1C. At baseline,
insulin secretion was signiﬁcantly lower
intheobese-type2diabeticgroup(vs.the
obese-NGT group; P  0.05). After the
study, there was a signiﬁcant increase in
insulin secretion in the obese-type 2 dia-
betic group, whereas the obese-NGT
groupshowedasigniﬁcantdecrease(both
P0.05).Insulin-stimulatedglucosedis-
posal was lower in the obese-type 2 dia-
beticgroupthanintheobese-NGTgroup,
but the intervention induced signiﬁcant
elevations in both groups (Table 1).
-Cell function (	C-Pep/	G  IR) is
shown in Fig. 1D. Baseline -cell function
wassigniﬁcantlyimpairedintheobese-type
2 diabetic group compared with the obese-
NGT group (P  0.05). After the lifestyle
intervention, -cell function was signiﬁ-
cantlyincreasedintheobese-type2diabetic
group (P  0.05), showing no alteration in
the obese-NGT group (P  0.05).
GIP responses
Figure 2A illustrates the changes in
plasma GIP secretory responses to OGTT
(	GIP0–30). Baseline 	GIP0–30 was not dif-
ferent between the obese-type 2 diabetic
and obese-NGT groups (P  0.05). After
the intervention, 	GIP0–30 increased in the
obese-type2diabeticgroup(P0.05)and
was nonsigniﬁcantly reduced in the obese-
NGT group (P  0.07). Further analysis
demonstrated that 	GIP0–30 was not re-
lated to changes in body weight or compo-
sition in these subjects (all P  0.05),
whereas a signiﬁcant relationship was iden-
tiﬁedbetweenthechangesin	GIP0–30and
the changes in insulin secretion (r  0.64,
P  0.005) (Fig. 2B).
CONCLUSIONS — After 3 months
of diet- and exercise-induced weight loss,
oral glucose–induced insulin secretion
was increased in older obese type 2 dia-
betic individuals. In older obese individ-
uals with NGT, the compensatory
postprandial hyperinsulinemia was sup-
pressed after the intervention. These
changes were found to be directly related
to the lifestyle-induced changes in oral
glucose–induced GIP responses. When
insulin secretion was corrected for the
decrementintheunderlyinginsulinresis-
tance, it became apparent that the im-
provement in insulin secretion in obese
individuals with NGT was driven by re-
duced insulin resistance. Yet, in the obese
type 2 diabetic individuals, the improve-
ment in insulin secretion appears to be a
resultofincreased-cellfunction.Forthe
ﬁrst time, using a physiological, incretin-
related measure of insulin secretion cor-
rected for the underlying rates of insulin-
stimulated glucose disposal, we have
demonstrated that nonsurgical and non-
pharmacological weight loss can promote
the restoration of insulin secretion in
olderobeseindividualswithtype2diabe-
tes via a mechanism related to increments
in GIP secretion from intestinal K-cells.
Caloric restriction studies have previ-
ously demonstrated the potential to
preserve -cell function in diabetic indi-
viduals (4,17–19). Bogardus et al. (20)
additionally found elevated insulin re-
sponses to OGTT after caloric restriction
and exercise-induced weight loss, and,
more recently, Dela et al. (21) and Slentz
et al. (4) provided strong evidence of ex-
ercise training–induced increases in
-cellfunctioninresponsetointravenous
glucose in type 2 diabetic and/or obese
patients. However, the nature of intrave-
nous techniques used in several previous
studies has not allowed for physiological
mechanistic insight into incretin-
mediated changes in insulin secretion.
The assessment of insulin secretory re-
Figure 1—Oral glucose–induced insulin secretion and -cell function. Older obese men and
women participated in a 3-month caloric restriction and exercise training–induced weight loss
intervention. Participants were stratiﬁed by oral glucose tolerance: obese-NGT and obese-type 2
diabeticgroups.Plasmaglucose(A)andC-peptide(B)responsestoOGTTweredetermined.After
the intervention, glucose responses were reduced in the obese-type 2 diabetic group; C-peptide
responses were increased in the obese-type 2 diabetic group, whereas they were reduced in the
obese-NGT group. Changes in oral glucose–induced insulin secretion (	C-Pep/	G) (C) and
insulin secretion corrected for the underlying insulin resistance (-cell function) (D) were also
assessed before and after the study. Insulin secretion was signiﬁcantly increased in the obese-type
2 diabetic group and decreased in the obese-NGT group, whereas -cell function signiﬁcantly
increasedintheobese-type2diabetesgrouponly,showingnochangeintheobese-NGTgroup. ,
mean prestudy data; f, mean poststudy data; errors bars represent S.E.M. *Signiﬁcant prestudy
vs. poststudy differences (P  0.05). #Prestudy differences between groups (P  0.05). a.u.,
arbitrary units; AUC, area under the curve.
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is related to the incretin axis and allows
clinical scientists to study -cell function
during a physiological postprandial per-
turbation. However, a change in the insu-
linsecretoryresponsemaynotnecessarily
be due to an alteration in -cell glucose
sensitivity or -cell insulin secretory ca-
pacity per se, it may also be driven by a
change in insulin sensitivity that would
consequently alter the exposure of the
-cell to circulating glucose. In this re-
spect, we applied the work of Gastaldelli
et al. (16) to correct insulin secretion for
the underlying peripheral tissue insulin
resistance. We previously demonstrated
that insulin secretion is reduced in obese
impaired glucose-tolerant individuals af-
ter a similar lifestyle intervention (11).
Here we show that in subjects exhibiting
insulin resistance yet normal glucose
tolerance, weight loss can dramatically
reverse the state of compensatory
hyperinsulinemia. Although our ﬁndings
do not demonstrate any alterations in
-cell function per se in such individuals,
it is interesting to note that the potential
progression toward impaired glucose tol-
erance that may occur if this group were
leftuntreatedhasprobablybeenreversed.
At the other end of the glucose tolerance
continuum, we demonstrate potential for
exercise- and diet-induced weight loss to
augment insulin secretion in type 2 dia-
betic patients via improvements in -cell
function, in addition to elevated rates of
insulin-stimulated glucose disposal and
reduced fasting and postprandial hyper-
glycemia.Therestorationofinsulinsecre-
tion in the diabetic state is crucial for
achievingoptimalglycemiccontrol,with-
out which uncontrolled hyperglycemia
would advance vascular inﬂammation
and oxidative stress, ultimately leading to
microvascular endothelial dysfunction
and macrovascular disease (3).
The dichotomy of “improved insulin
secretion” in diabetic versus nondiabetic
individuals is highlighted by this current
study:reversalofinadequatepostprandial
insulinemia in diabetic individuals versus
reversal of compensatory hyperinsulin-
emia in nondiabetic individuals. Expo-
sure of the -cell to chronic hyper-
glycemia leads to functional impairment
or glucotoxicity (22). Thus, relief of ex-
treme hyperglycemia and therefore toxic-
ityinourdiabeticpopulationmayexplain
the augmentation of postprandial insulin
secretion. However, our diabetic subjects
alsodemonstrateanincreaseinGIPsecre-
tion after the intervention. The mecha-
nisms behind these changes are not
understood, but our correlation analyses
negatetheeffectsofchangesinbodycom-
position; however, it has been demon-
strated that chronic hyperglycemia can
downregulatepancreaticGIPreceptorex-
pression (23) and also increase GIP gly-
cation, thus rendering the peptide
dysfunctional with respect to insulino-
genic capacity (24). This process may
translate to the chronic hyperglycemic
state in diabetes, where glucotoxicity is
systemic and may therefore have the po-
tential to impair GIP functional capacity
or indeed intestinal K-cell secretion. Al-
though caution must be used when cor-
relativeinterpretationsaremadewithlow
numbers of subjects, our ﬁnding that
weight loss–induced changes in GIP are
related to changes in insulin secretion
warrants further attention. Future re-
searchersshouldalsoexaminemorethor-
oughly the incretin axis to include the
insulinogenic protein, GLP-1.
Itisalsointerestingtonotethatafter3
months of lifestyle intervention neither
hyperglycemia nor insulin secretion is
normalized. Perhaps alternative treat-
ment modalities are sensible. In recent
years, surgical techniques and exenatide
compounds have emerged (13) and re-
ceived attention for their potential to ini-
tiate insulin secretion in severely obese
diabetic patients. Recent data show that
Roux-en-Y gastric bypass can increase
pancreatic -cell insulin secretory capac-
ity via alteration of incretin signaling and
can normalize hyperglycemia in up to
Figure2—ChangesinplasmaGIPsecretion.A:ChangesintotalplasmaGIPsecretoryresponses
to OGTT (	GIP0–30) (obese-NGT group n  10; obese-type 2 diabetic [T2DM] group n  8)
were assessed before and after the 3-month weight loss intervention.  , mean data before the
intervention; f, mean data after weight loss; error bars represent S.E.M. 	GIP0–30 was signiﬁ-
cantly increased in the obese-type 2 diabetic group. B: Linear regression analyses revealed a
signiﬁcant correlation between the changes in plasma GIP responses to oral glucose and oral
glucose-induced insulin secretion (r  0.64, P  0.005). f, obese-NGT group; ‚, obese-type 2
diabetic group. *Signiﬁcantly increased in obese-T2DM compared to obese-NGT (P  0.05).
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the relative impact of lifestyle intervention
on -cell function may seem small. How-
ever,moreprolongedinterventionsdemon-
strate even more dramatic improvements
(4), and indeed the goal of clinical care is
on-going dietary monitoring and physical
activity. In the U.S. health care system,
pharmaceutical and surgical options are a
ﬁnancial burden and not accessible to all,
leaving low-cost lifestyle programs as a uni-
versal and valuable option.
In summary, we have furthered the
work of prior investigations with intrave-
nous methods by using an oral glucose
technique to assess incretin-related insu-
lin secretion and account for -cell glu-
cose exposure. We demonstrate that
lifestyle intervention not only relieves the
underlying insulin resistance in obesity
butinolderobesetype2diabeticindivid-
uals it also has the potential to reverse
-cell dysfunction and therefore help re-
duce the risk of vascular disease. We also
present new data demonstrating that ele-
vations in in vivo insulin secretion in re-
sponse to a physiological orally ingested
glucose load is related to changes in post-
prandial GIP responses. This information
highlightsapotentialmechanismtoshow
that modiﬁcation of intestinal incretin se-
cretion after 3 months of mild caloric re-
striction and aerobic exercise training
may explain the improvement in -cell
function in type 2 diabetic patients. A re-
lationship between the changes in incre-
tin secretion and -cell function after
lifestyle intervention has never before
been demonstrated in type 2 diabetes.
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